Recommended Antidepressant for Illness Anxiety Disorder
SSRIs (selective serotonin reuptake inhibitors) are the recommended first-line antidepressant treatment for Illness Anxiety Disorder, with sertraline being a particularly well-supported choice given its established efficacy across anxiety disorder spectrum and favorable side effect profile.
Rationale and Evidence Base
The evidence for treating Illness Anxiety Disorder (IAD) specifically is limited, as this is a relatively newly defined diagnostic entity in DSM-5. However, IAD shares substantial overlap with other anxiety disorders in terms of pathophysiology and treatment response 1, 2.
First-Line Pharmacotherapy
SSRIs represent the gold standard for anxiety disorder treatment:
- Sertraline is consistently identified as a first-line agent across anxiety disorders with demonstrated efficacy (SMD -0.55 to -0.67 compared to placebo) 1
- SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine extended-release are equally effective alternatives 1, 3, 2
- Both medication classes show small to medium effect sizes with good tolerability profiles 1
Practical Prescribing Approach
Starting the medication:
- Begin with a subtherapeutic "test" dose to minimize initial anxiety or agitation that can occur with SSRIs 4
- Increase dosage in smallest available increments at 1-2 week intervals for shorter half-life SSRIs (sertraline, citalopram) 4
- Titrate to the therapeutic range based on tolerability and response, not necessarily to maximum doses
Duration of treatment:
- Continue medications for 6-12 months after achieving remission 3
Important Caveats
Drug-specific considerations:
- Citalopram/escitalopram may have the lowest propensity for drug-drug interactions among SSRIs, but citalopram is contraindicated at doses >40mg/day due to QT prolongation risk 4
- Paroxetine carries higher risk of discontinuation syndrome and has been associated with increased suicidal thinking compared to other SSRIs 4
- Fluvoxamine has greater potential for drug-drug interactions via multiple CYP450 pathways 4
Avoid benzodiazepines as routine treatment due to addiction potential and long-term adverse effects, despite their historical use in anxiety disorders 3, 5
Clinical Context for IAD
Research demonstrates that IAD and somatic symptom disorder show minimal differences in treatment response, comorbidities, and illness course 6. This supports using the same pharmacological approach proven effective for other anxiety disorders, particularly given that health anxiety responds to standard anxiety disorder treatments.
Combination treatment with cognitive behavioral therapy plus an SSRI may be superior to monotherapy alone, though this evidence derives primarily from other anxiety disorders 4.